top of page


Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

To help the body’s immune response against tumors, doctors have created a medicine called Voyager V1 or VV1. This is a synthetic virus that intensifies the anti-tumor immune responses and affects only the tumor cells and not the healthy ones. This research study will study the benefits and effects of the treatment with Voyager V1 when fighting tumors, and see if it is safe when combined with the drug, Cemiplimab, in patients with advanced and progressing types of the cancers that progress on treatment with Checkpoint Inhibitors (CPIs). Drugs called “checkpoint inhibitors” work by releasing a natural brake on your immune system so that immune cells can recognize and attack tumors. Cemiplimab is a monoclonal antibody which is an immune therapy. The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:


Clinical Trial Site: Sinai

To see all available clinical trials click here.

Recent Posts

See All


An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of


A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positiv


10551 A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-Mutant Tumors This research study is studying a new type of cancer treatment. The trea


bottom of page